🏛️ Verified NIH Record • Updated 2026-03-31
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer (NCT06497569)
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer (STRONG-GEC)
🟢 Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: H. Lee Moffitt Cancer Center and Research Institute
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine how the STRONG intervention compares with usual care for reducing malnutrition among gastroesophageal cancer patients.
Who can join: Review the eligibility criteria below.
Location: Moffitt Cancer Center — Tampa, Florida
Age range: 18 Years
🧪 Interventions in This Study
- Dietitian Consultation (BEHAVIORAL)
- Survey (BEHAVIORAL)
- Fitbit Data Collection (BEHAVIORAL)
- Referral to Dietitian (BEHAVIORAL)
- Social Determinants of Health Survey (SDOH) (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Moffitt Cancer Center — Tampa, Florida
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
📞 Contact the Study Coordinator
Phone: (813) 745-6426
Email: Emma.Hume@moffitt.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in GastroEsophageal Cancer
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) — Gilbert, Arizona
- Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer — Tampa, Florida
- REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer — Baltimore, Maryland
Explore by condition: All GastroEsophageal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.